Methadone and buprenorphine/naloxone are effective opioid agonist therapies (OAT) for opioid use disorder. But some people don’t achieve the outcomes they hope for. Genetic factors are known to influence a person’s risk of developing opioid use disorder, but there is little research on whether they might influence the likelihood that OAT will be effective.

Researchers investigated whether certain gene variants are associated with treatment outcomes in people receiving methadone or buprenorphine/naloxone for prescription-type opioid use disorder.

REGISTER TODAY!

DESCRIPTION

Methadone is a first-line treatment for opioid use disorder and its use is associated with reduced morbidity, mortality, blood-born viral infections and social harms. Despite these benefits, methadone remains a poorly understood and stigmatized medication. Comprehensive primary care that includes integrated opioid agonist therapy results in improved preventative health screening and higher client satisfaction.

REGISTER TODAY!

DESCRIPTION

We’re almost ready to share the line-up for the METAHI 2022 conference. It’s looking like a great two days of sessions, interactive workshops and poster presentations on topics ranging from injectable OAT to working with peers.

Are you a physician or nurse practitioner who works with people with opioid use disorder? 

Register for the webinar here.

Taking Group Work Online

Thu, Nov 19, 2020 12:00 PM - 1:30 PM EST

Presented by: Dr. Ellen Sue Mesbur & Dr. Barbara Muskat

Please find below the consensus interim guideline for management of opioid agonist therapy (OAT) during the COVID-19 pandemic:

http://metaphi.ca/assets/docum...reatmentGuidance.pdf

This event will be live webcasted as well, please log in at: http://camh.adobeconnect.com/june7_md/ 

Ensure you have signed in 15 minutes prior to the start time, in case we need to troubleshoot audio or video.

LEARNING OBJECTIVES:

1. Identify challenges relating to acute pain management for patients on opioid agonist therapy.
2. Review literature relating to acute and perioperative pain management for patients maintained on buprenorphine and methadone.
3. Discuss gaps in the literature and highlight relevance to our practice.